Unveiling the Role of IL-10-Neutralising Autoantibodies in Pediatric-Onset Inflammatory Bowel Disease: Prevalence, Persistence, and Clinical Implications
IL-10-neutralising autoantibodies were identified in approximately 2% of pediatric-onset IBD patients without known monogenic causes.
These autoantibodies persist longitudinally under standard immunosuppressive therapies but disappear following hematopoietic stem-cell transplantation (HSCT).
Presence of IL-10 neutralising autoantibodies may represent a unique immunological subtype with distinct clinical features and treatment considerations in pediatric IBD.
Screening for IL-10 autoantibodies via functional assays could guide personalized management strategies in this patient population.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
